The stock of this Pharma Company Hits 20 per cent Upper Circuit with High Intraday Volumes; FIIs Increased their Stake in Q2 FY25
The stock has given returns of 36 per cent returns in the last 6 months.
Lincoln Pharmaceuticals Limited witnessed a significant surge in its stock price on December 3, 2024, closing up by 20 per cent at Rs 763.20 per share. The stock hit its upper circuit amidst unusually high trading volumes of around 11 lakh shares across NSE and BSE, compared to its average daily volumes of under 1 lakh shares. The company's market capitalisation has now crossed Rs 1,500 crore, attracting attention as an institutional favourite.
DSIJ’s 'multibagger Pick’ service recommends well researched multibagger stocks with High Returns potential. If this interests you, do download the service details here.
Market speculation suggests Foreign Institutional Investors (FIIs) are actively accumulating shares due to attractive valuations and strong growth prospects. Institutional stakes have steadily risen, with FII and DII holdings increasing from under 1 per cent in March 2022 to 5.2 per cent by September 2024.
Lincoln Pharma, a debt-free company, reported an annual net profit exceeding Rs. 100 crore and investments of over Rs 164 crore as of September 2024. The company has consistently grown profits every fiscal year from FY13 to FY23, achieving a Compound Annual Growth Rate (CAGR) of over 22 per cent in net profits, 19 per cent in EBITDA, and 10 per cent in revenue over the past decade.
The company exports to over 60 countries and recently expanded into the Canadian market. Approvals from TGA - Australia and EU GMP further position Lincoln Pharma for global growth. With product registration efforts underway for its Cephalosporin plant in Mehsana, the company aims to achieve Rs 750 crore in revenue by FY26.
Lincoln Pharma's strong liquidity, zero-term debt, and robust return ratios continue to bolster investor confidence, as the company remains poised for sustained growth.
Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.
The shares of the company are trading at Rs 754 with a market cap of Rs 1,529 crore. The stock has given returns of 36 per cent returns in the last 6 months. Investors should keep this Small-Cap stock on the radar.
Disclaimer: The article is for informational purposes only and not investment advice.